Modifying neural stem cells improves their therapeutic efficacy

November 02, 2009

Stem cells isolated from the brain of adult mice (adult neural stem cells [aNSCs]) have shown very modest therapeutic effects in a mouse model of the chronic inflammatory neurodegenerative disease multiple sclerosis. But now, Guang-Xian Zhang and colleagues, at Thomas Jefferson University, Philadelphia, have developed an approach to enhance the therapeutic effects of aNSCs in this model of multiple sclerosis. Specifically, the researchers genetically engineered aNSCs to express the anti-inflammatory molecule IL-10 and found that these cells induced more extensive functional and pathological recovery from ongoing disease than did nonengineered aNSCs. Importantly, the IL-10-aNSCs mediated their effects in multiple ways, suppressing immune system attack of nerve cells, promoting nerve cell repair, and promoting production of the nerve cell protective sheath. The authors hope these results might increase the chance that aNSC-based therapies might one day be developed for clinical use.
-end-
TITLE: Adult neural stem cells expressing IL-10 confer potent immunomodulation and remyelination in experimental autoimmune encephalitis

AUTHOR CONTACT:
Guang-Xian Zhang
Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Phone: (215) 955-8935; Fax: (215) 503-5848; E-mail: Guang-Xian.Zhang@jefferson.edu.

View this article at: http://www.jci.org/articles/view/37914?key=NKxgD7l4U2cHdaVxIjn7

JCI Journals

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.